Zelluna ASA 2024 AR2
The report details the company's performance during 2024, a transformative year marked by negative clinical trial results for its lead UV1 cancer vaccine program and a subsequent business combination with Zelluna Immunotherapy AS. Completed in March 2025, this transaction shifted the company's focus toward developing off-the-shelf T-cell receptor guided natural killer (TCR-NK) cell therapies, particularly the lead asset ZI-MA4-1. Financially, the company recognized government grants of MNOK 5.4 and recorded a total loss of MNOK 201.1, while fully impairing its goodwill, licenses, and patents related to the UV1 and TET/MultiClick technologies. On the ESG front, the company reported zero workplace fatalities, a sickness absence rate of 0.1%, and estimated Scope 2 emissions of 1.0 tonne of CO2e.
Company: Zelluna ASA
Sector: Health Care
Country: Norway
Year: 2024
Type: AR2
Pages: 104
Zelluna ASA
Annual Report
The report details the company's performance during 2024, a transformative year marked by negative clinical trial results for its lead UV1 cancer vaccine program and a subsequent business combination with Zelluna Immunotherapy AS. Completed in March 2025, this transaction shifted the company's focus toward developing off-the-shelf T-cell receptor guided natural killer (TCR-NK) cell therapies, particularly the lead asset ZI-MA4-1. Financially, the company recognized government grants of MNOK 5.4 and recorded a total loss of MNOK 201.1, while fully impairing its goodwill, licenses, and patents related to the UV1 and TET/MultiClick technologies. On the ESG front, the company reported zero workplace fatalities, a sickness absence rate of 0.1%, and estimated Scope 2 emissions of 1.0 tonne of CO2e.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees